Background: Recent guidelines suggest screening high-risk women in early pregnancy for gestational diabetes (GDM); however, there is little evidence to support this.
INTRODUCTION
Gestational diabetes mellitus (GDM) is a common obstetric complication, affecting 12.7% of Australian pregnancies 1 and has maternal and neonatal implications. 2 Treatment of GDM has been shown to reduce maternal and neonatal complications. 3, 4 In many countries, GDM screening occurs at around 28 weeks gestation, but recent guidelines have suggested that screening for GDM should also be conducted in early pregnancy in highrisk groups, because early detection and treatment may improve outcomes. 5, 6 The Australian Diabetes in Pregnancy (ADIPS) guideline recommends early screening with a glucose tolerance test 
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polycystic ovarian syndrome (PCOS), ethnicity including Asian, Indian subcontinent, Aboriginal, Torres Strait Islander, Pacific
Islander, Maori, Middle Eastern, non-White African, use of corticosteroids or antipsychotics or a family history of type 2 DM or GDM. 5 There is limited published data regarding obstetric and neonatal outcomes in women diagnosed with GDM in early pregnancy and so we hypothesised that, in women with increased risk factors for GDM, diagnosis of GDM in the first half of pregnancy would be associated with adverse obstetric or neonatal outcomes compared to similar women who are diagnosed with GDM at 24-28 weeks gestation, or those who do not have GDM.
METHODS
The study was conducted at an Australian tertiary hospital. Women were included if they underwent a 75 g oral GTT between 1 January, 2005 and 8 January, 2016, at <20 weeks gestation, with a singleton pregnancy, and who then completed an GTT in the second half of pregnancy if the initial test was negative. This time frame was used to ensure similar obstetric and endocrine practices. It was not possible to identify the indication for the performance of the early GTT, but was presumed that all women who had an early GTT had a risk factor, as defined by the clinician. Data were collected on region of birth, maternal age, BMI and parity. The gestational age at the time of the GTT was determined from the estimated due date (identified from the medical record) and the date of the GTT. Missing late GTT values were sourced from either electronic or paper records. Until 1 January, 2014, GDM was diagnosed if the fasting value was ≥5.5 mmol/L or the two-hour value was ≥8.0 mmol/L. 7 From 1 January, 2014, GDM was diagnosed if the fasting value was ≥5.1 mmol/L, one-hour value ≥10.0 mmol/L or two-hour value ≥8.5 mmol/L. 8 The diagnosis of GDM was based on the criteria in use at the time of GTT. Maternal and neonatal outcomes were obtained from the hospital's electronic birthing outcome system, which is completed by trained midwives.
Approval to conduct the research was provided by the Mercy Hospital Human Research and Ethics committee, R15-52.
Outcome measures
The primary outcomes were an obstetric composite and a neo- The hypothesis that women who are diagnosed with early GDM are at higher risk of developing poor pregnancy outcomes was investigated using appropriate regression models de- 
RESULTS
Baseline characteristics
Of the 44 675 pregnant women who underwent a GTT during the specified time period, 888 women fulfilled the inclusion criteria. The demographics of the women included in the study are detailed in Table 1 . The demographics of the women who were not included were not available. Women without GDM were younger than women with early or late GDM (P = 0.001) and more likely to be nulliparous; however, there was no difference between groups in BMI or gestational age between groups at the first GTT. 
GDM diagnosis
Associations between GDM and pregnancy outcomes
No statistically significant increase was identified in the odds of the obstetric composite outcome in women who developed early or late GDM when compared to no GDM, following adjustment for maternal BMI, age, parity and region of birth (early OR 1.16 95% CI 0.79-1.71 P = 0.46; late OR 0.78 95% CI 0.53-1.12 P = 0.23; Table 2 ). The odds of an infant demonstrating one or more components of the neonatal composite was significantly increased in women with early GDM, but not late GDM compared to no GDM There was no excessive collinearity identified for the obstetric or neonatal composite.
DISCUSSION
The objective of our study was to determine whether women with risk factors for GDM who were diagnosed with early GDM experienced greater adverse pregnancy outcomes compared to similar women with late GDM or women without GDM in a retrospective analysis.
Following adjustment for maternal BMI, age and region of birth, we found no evidence that women with early GDM were more likely to experience the obstetric composite outcome than women with late GDM or no GDM. There was an increase in the odds of the neonatal composite outcome, which was predominantly due to an increase in neonatal hypoglycaemia. The increased rates of neonatal hypoglycaemia may be due to a true increase in neonatal hypoglycaemia or increased testing of the infants because <0.001 †Obstetric composite: caesarean section, neonatal birthweight >4500 g or >90th centile for gestational age, third or fourth degree perineal tear or shoulder dystocia. ‡Neonatal composite: Apgar <7 at 5 min, NICU/SCN admission, neonatal hypoglycaemia or major birth defect.
aOR, adjusted odds ratio; GDM, gestational diabetes mellitus; HDC, high dependency care; NICU, neonatal intensive care; OR, odds ratio; PE, pre-eclampsia; PIH, pregnancy-induced hypertension; PPH, postpartum haemorrhage; SCN, special care nursery. Induction of labour: n = 436 (no GDM), 119 (early GDM) 131 (late GDM) excluding women with elective caesarean section. Data is n (%) adjusted for maternal BMI, age, parity and region of birth.
of the GDM diagnosis, as infants of women without GDM do not
have their blood glucose level tested unless symptomatic or large for gestational age. Data on the numbers of neonatal blood sugar tests, or on negative results were not available. The rate of induction was also increased, which is consistent with hospital guidelines advising induction of labour for women with GDM.
There were 38.4% of women in the cohort diagnosed with GDM, a figure almost three-fold higher than the current prevalence of GDM in Australia. 1 This is likely to be because the women had risk factors for GDM, as identified by their clinician.
Of the women diagnosed with GDM, 49.9% were diagnosed in early pregnancy and 50.1% in later pregnancy. These proportions are different from other reported series, in which higher proportion of women have been diagnosed in later pregnancy, from 71 to 88%. [10] [11] [12] Early pregnancy testing may detect either women with a false positive GDM result due to high fasting glucose in early pregnancy 13 or women with underlying type 2 diabetes. Thirty women underwent a GTT ≤12 weeks gestation and 12 were diagnosed with early GDM. It is possible that these women were incorrectly diagnosed with early GDM, as increased fasting plasma glucose occurs in the first trimester. 14, 15 The inclusion of 12 women with a false positive diagnosis may have decreased the true association between early GDM and pregnancy outcomes. Some women who had an early positive diagnosis of GDM may have had previously undiagnosed type 2 diabetes; however, we were not able to confirm postnatal diagnoses of type 2 diabetes.
The strengths of our study are that it is the largest published cohort that we are aware of which includes a relevant control group of similar women, and includes adjustment for important maternal factors which impact on pregnancy outcomes.
The cohort is of mixed ethnicity, making the result more able to be generalised.
This study has some limitations, including using retrospective data over a ten years time period in which time there were inevitably some changes in obstetric practice in the institution, and changes in the diagnostic criteria for GDM. However, the analysis of outcome was based on the diagnostic criteria in use at the time of diagnosis. We were not able to determine the risk factors for each woman that prompted clinicians to request an early GTT. It is a single institution study, which may limit generalisability.
We did not find an increase in the odds of the obstetric composite outcome, or individual components of the obstetric composite, but others have demonstrated increased rates of adverse outcomes in women with early GDM including preeclampsia, caesarean section and macrosomia. 11, 12, 16, 17 These differences may be due to small sample size, cohorts extending over prolonged periods and encompassing changes in diabetes management and obstetric management, and lack of an appropriate control group. Because of the independent associations between increased BMI or advanced maternal age and many important obstetric outcomes, data which are not adjusted for these covariates are more likely to show an association between early GDM and these outcomes. Other studies have not demonstrated increases in adverse outcomes when results are adjusted for maternal characteristics. 10, 16, 18 Conversely, some authors have found higher prevalence of polyhydramnios and preterm birth in women diagnosed in later pregnancy compared to early pregnancy which they attributed to better control of diabetes with early diagnosis.
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Women who were diagnosed with GDM were referred for multidisciplinary care, including diet and lifestyle management, and pharmacological intervention as required. It is possible that return to normoglycaemic values returned the risk profile to baseline, although this has not been demonstrated in other cohorts of women with GDM diagnosed as part of routine screening. 20 We do not have information on the degree of compliance with therapy or level of blood sugar control in the cohort.
CONCLUSION
There has been little published information to date regarding the relationship between GDM diagnosed prior to 20 weeks gestation and pregnancy outcomes. In our study, there was no significant difference in the composite obstetric outcome between the groups but an increase in the neonatal composite outcome for women with early GDM. Outcomes which are dependent on the clinicians' knowledge of the diagnosis of GDM, induction of labour and diagnosis of neonatal hypoglycaemia,
were increased in women with GDM, compared to women who never developed GDM. The results of our study suggest that following adjustment for maternal confounders, early GDM does not have a significant impact on maternal outcomes but may impact on neonatal outcomes. This is consistent with the published recommendations of a number of authorities suggesting that early pregnancy screening for GDM does not provide additional maternal health benefits. 21, 22 A prospective, randomised, multicentre trial would help to better understand the role of screening and treatment for early GDM and its effect on pregnancy outcomes.
